The HDAC inhibitor, TSA prevents the acquisition of secondary morphological features of differentiating PMOs with concurrent alteration in the expression profiles of ncRNAs. (A-D) Immunofluorescence micrographs demonstrating the profiles of OL lineage species in the absence (A, B) or presence of TSA (C, D) at 24 h and 48 h. (E) The fold change in ncRNA expression in TSA treated versus untreated PMOs at 24 h and 48 h. (F) The fold change in Neat1 expression in TSA treated versus untreated PMOs under CNTF presence (instructive) or absence (stochastic) with concurrent PDGF-AA factor withdrawal. Immunofluorescence micrographs of CNTF naïve, TSA treated cells and fold-change as determined by Q-PCR for remaining ncRNAs is illustrated in Additional file 15. (Error bars indicate standard error with asterisks indicated significant fold change at p > 0.05).
Mercer et al. BMC Neuroscience 2010 11:14 doi:10.1186/1471-2202-11-14